{"id":"continued-paroxetine-cr","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-20","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Sweating"},{"rate":"5-10","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL6067650","moleculeType":"Small molecule","molecularWeight":"749.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine selectively inhibits the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin concentration in the synaptic space. This enhanced serotonergic neurotransmission is thought to improve mood and reduce anxiety symptoms. The CR (controlled-release) formulation provides sustained drug delivery over 24 hours, improving tolerability and compliance.","oneSentence":"Paroxetine CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:57.853Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Social anxiety disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"}]},"trialDetails":[{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT00113295","phase":"PHASE4","title":"Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-02","conditions":"Anxiety Disorder","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continued Paroxetine CR","genericName":"Continued Paroxetine CR","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paroxetine CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}